Paclitaxel (albumin-bound) for Pancreatic ductal adenocarcinoma

Stratification factors

• basal CA19.9 level (<5 ULN vs ≥ 5ULN)
• centre
• treatment assigned by first randomization (for second randomization)

Inclusion criteria

• {"criterion_text":"- Cyto/histological diagnosis of pancreatic ductal adenocarcinoma"}
• {"criterion_text":"- Women must not be on pregnancy or lactation;"}
• {"criterion_text":"- Patient of child-bearing potential must agree to use two medically acceptable methods of contraception (one for the patient and one for the partner) during the study and for a minimum of the following 6 months; this applies to patients of both sexes. [appendix 4];"}
• {"criterion_text":"- Patient information and signed written informed consent"}
• {"criterion_text":"- Clinical stage I-III disease according to TNM 8th Ed. 2017 [appendix 1];"}
• {"criterion_text":"- Resectable or borderline resectable disease, as anatomically defined according to NCCN Guidelines Version 1.2020 – Pancreatic Adenocarcinoma [appendix 2] and biologically defined according to the International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017 (CA 19.9 > 500 IU/ml) (Isaji et al., 2018)"}
• {"criterion_text":"- Karnofsky Performance Status > 60%"}
• {"criterion_text":"- Age  18 and ≤ 75 years"}
• {"criterion_text":"- Adequate bone marrow function (GB ≥ 3500/mm3, neutrophils ≥1500/mm3, platelets ≥ 100000/mm3, Hb ≥10 g/dl);"}
• {"criterion_text":"- Adequate kidney function (serum creatinine < 1.5 mg/dL);"}
• {"criterion_text":"- Adequate liver function: - ALT and AST < 3 ULN - Serum total bilirubin ≤ 1.5 ULN or in subjects with biliary stenting ≤ 2 ULN"}
• {"criterion_text":"- No prior treatment (chemotherapy, radiotherapy and/or surgery) for pancreatic cancer"}

Exclusion criteria

• {"criterion_text":"- Other types of non-ductal tumor of the pancreas, including endocrine tumors or acinar cell adenocarcinoma, cystadenocarcinoma and other periampullary malignancies"}
• {"criterion_text":"- Prior (within 1 year) or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin"}
• {"criterion_text":"- Symptomatic duodenal stenosis"}
• {"criterion_text":"- Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment"}
• {"criterion_text":"- Known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications"}
• {"criterion_text":"- Clinical stage IV (including ascites or malignant pleural effusion) disease according to TNM 8th Ed. 2017 [appendix 1];"}
• {"criterion_text":"- Locally advanced disease according to NCCN Guidelines Version 1.2020 – Pancreatic Adenocarcinoma [appendix 2];"}
• {"criterion_text":"- Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the subject's safety or the study data integrity. These include, but are not limited to: a. History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa) b. History of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies c. History of the following within 6 months prior to Cycle 1 Day 1: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or ECG abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder"}
• {"criterion_text":"- Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study"}
• {"criterion_text":"- Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study"}
• {"criterion_text":"- Any condition that confounds the ability to interpret data from the study"}
• {"criterion_text":"- Any familiar, sociologic or geographic conditions that can potentially interfere with the adhesion to the protocol or to the follow-up;"}
• {"criterion_text":"- Pre-existing neuropathy"}
• {"criterion_text":"- c.1679GG, c.1905+1AA, c.2846TT mutations in homozygous in DPYD gene. Dose modification according to DPYD and UGT1A1 mutations are reported in Table 1 (https://www.aiom.it/wp-content/uploads/2019/10/2019_Racc-analisi-farmacogenetiche.pdf.)"}
• {"criterion_text":"- Inflammatory disease of the colon or rectum, or occlusion or sub-occlusion of the intestine"}
• {"criterion_text":"- Concurrent treatment with other experimental drugs"}
• {"criterion_text":"- Fructose intolerance."}

Primary endpoints

• {"endpoint_text":"- EFS, defined as the time from randomization to: RECIST 1.1 progression [At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study","definition_or_measurement_approach":"Defined as the time from randomization to RECIST 1.1 progression (At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study)."}

Secondary endpoints

• {"endpoint_text":"- OS","definition_or_measurement_approach":""}
• {"endpoint_text":"- RECIST 1.1 response rate","definition_or_measurement_approach":"Measured by RECIST 1.1 criteria"}
• {"endpoint_text":"- CA19.9 response rate","definition_or_measurement_approach":"Measured by changes in CA19.9 biomarker levels"}
• {"endpoint_text":"- complete pathologic response","definition_or_measurement_approach":""}
• {"endpoint_text":"- resectability rate","definition_or_measurement_approach":""}
• {"endpoint_text":"- surgical mortality and morbidity rate","definition_or_measurement_approach":""}
• {"endpoint_text":"- intra- and post-operative metastasis rate","definition_or_measurement_approach":""}
• {"endpoint_text":"- N0 and R0 resections rate","definition_or_measurement_approach":""}
• {"endpoint_text":"- patients reported outcomes","definition_or_measurement_approach":""}
• {"endpoint_text":"- treatment toxicity","definition_or_measurement_approach":""}

Italy

Earliest CTIS Part Ii Submission Date

16-10-2024

Latest Decision Or Authorization Date

18-11-2024

Processing Time Days

33

Number Of Sites

26

Number Of Participants

261

Primary sponsor

Full Name

Associazione Italiana Per Lo Studio Del Pancreas

Organisation Type

Patient organisation/association

Country Of Registered Address

Italy